id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-E-0246-0008,FDA,FDA-2011-E-0246,Letter from U.S. Patent and Trademark Office to Foley & Lardner LLP,Other,Letter(s),2014-07-02T04:00:00Z,2014,7,2014-07-02T04:00:00Z,,2014-07-02T15:50:34Z,,0,0,0900006481787f4d
FDA-2011-E-0246-0007,FDA,FDA-2011-E-0246,FDA\CDER to U.S. Patent and Trademark Office Letter,Other,Letter(s),2012-12-27T05:00:00Z,2012,12,2012-12-27T05:00:00Z,,2012-12-27T16:46:12Z,,0,0,090000648119c8d0
FDA-2011-E-0246-0006,FDA,FDA-2011-E-0246,FDA\CDER to United States Patent and Trademark Office - Letter,Other,Letter(s),2012-04-09T04:00:00Z,2012,4,2012-04-09T04:00:00Z,,2012-04-09T13:19:57Z,,0,0,0900006480feb781
FDA-2011-E-0246-0005,FDA,FDA-2011-E-0246,Determination of Regulatory Review Periods for Patent Extension: TEFLARO,Notice,General Notice,2012-04-06T04:00:00Z,2012,4,2012-04-06T04:00:00Z,2012-05-06T03:59:59Z,2014-07-02T15:41:54Z,2012-08339,0,0,0900006480feaa07
FDA-2011-E-0246-0004,FDA,FDA-2011-E-0246,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2012-03-12T04:00:00Z,2012,3,2012-03-12T04:00:00Z,,2024-03-13T17:56:51Z,,0,0,0900006480fd39b0
FDA-2011-E-0246-0003,FDA,FDA-2011-E-0246,FDA\CDER to United States Patent and Trademark Office - Letter,Other,LET-Letter,2011-06-09T04:00:00Z,2011,6,2011-06-09T04:00:00Z,,2011-06-09T12:59:41Z,,0,0,0900006480e42948
FDA-2011-E-0246-0002,FDA,FDA-2011-E-0246,U.S. Patent and Trademark Office - Letter,Other,LET-Letter,2011-04-05T04:00:00Z,2011,4,2011-04-05T04:00:00Z,,2013-07-27T23:49:16Z,,0,0,0900006480c1bf1c
FDA-2011-E-0246-0001,FDA,FDA-2011-E-0246,Takeda Pharmaceutical Company LTD (Foley & Lardner LLP) - Patent Extension Application,Other,APP-Application,2011-04-05T04:00:00Z,2011,4,2011-04-05T04:00:00Z,,2013-07-27T23:49:16Z,,0,0,0900006480c1bf1a